The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
September 15, 2025
Sunvozertinib (Zegfrovy) for NSCLC (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Sunvozertinib (Zegfrovy) for NSCLC (online only)
September 15, 2025 (Issue: 1737)
Sunvozertinib (Zegfrovy – Dizal), an oral kinase
inhibitor, has received accelerated approval from the
FDA for treatment of adults with locally advanced or
metastatic non-small cell lung cancer (NSCLC) with
epidermal growth factor receptor...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.